Home Other Building Blocks PIBOSEROD,2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE, N-((1-BUTYL-4-PIPERIDINYL)METHYL)-3,4-DIHYDRO-

PIBOSEROD,2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE, N-((1-BUTYL-4-PIPERIDINYL)METHYL)-3,4-DIHYDRO-

CAS No.:
152811-62-6
Catalog Number:
AG00ABLA
Molecular Formula:
C22H31N3O2
Molecular Weight:
369.5004
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥95%
1 week
United States
$91
- +
5mg
≥95%
1 week
United States
$169
- +
10mg
≥95%
1 week
United States
$265
- +
25mg
≥95%
1 week
United States
$535
- +
50mg
98%
1 week
United States
$807
- +
Product Description
Catalog Number:
AG00ABLA
Chemical Name:
PIBOSEROD,2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE, N-((1-BUTYL-4-PIPERIDINYL)METHYL)-3,4-DIHYDRO-
CAS Number:
152811-62-6
Molecular Formula:
C22H31N3O2
Molecular Weight:
369.5004
MDL Number:
MFCD00923681
IUPAC Name:
N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
InChI:
InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)
InChI Key:
KVCSJPATKXABRQ-UHFFFAOYSA-N
SMILES:
CCCCN1CCC(CC1)CNC(=O)c1c2OCCCn2c2c1cccc2
UNII:
4UQ3S81B25
Properties
Complexity:
492  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
369.242g/mol
Formal Charge:
0
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
369.509g/mol
Monoisotopic Mass:
369.242g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
46.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7  
Literature
Title Journal
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists. Bioorganic & medicinal chemistry 20101215
Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. European journal of heart failure 20090801
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines. Bioorganic & medicinal chemistry 20090315
Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat. Journal of pharmacological and toxicological methods 20060101
Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle. World journal of urology 20050601
Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification. Bioorganic & medicinal chemistry letters 20050315
The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. British journal of pharmacology 20041101
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20040101
Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats. European journal of pharmacology 20030425
5-HT4 receptor ligands: applications and new prospects. Journal of medicinal chemistry 20030130
Synthesis and pharmacological activity of metabolites of the 5-HT(4) receptor antagonist SB-207266. Bioorganic & medicinal chemistry 20010801
Serotonin-4 receptor antagonists reverse cocaine-induced cardiac arrhythmia. Life sciences 19980101
Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase. Neuroreport 19971020
Properties